ANIP
ANI Pharmaceuticals, Inc.
ANIP
ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected
ANI Pharmaceuticals is rated Buy at $80, with a 12-month fair value set at $95, as the current valuation undervalues 2027 earnings potential. 2026 results are depressed by upfront gout expansion cost
PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from
PRINCETON, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced positive topline data from its Phase 4, open-label, single-arm SYNCHRON